Filling the gaps in COPD: the TRIBUTE study

Affiliations

¹ Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona 08036, Spain; CIBERES, Barcelona, Spain. Electronic address: aagusti@clinic.cat.

Comment

Alvar Agusti. Lancet. 2018.

. 2018 Mar 17;391(10125):1004-1006.

doi: 10.1016/S0140-6736(18)30252-6. Epub 2018 Feb 9.

¹ Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona 08036, Spain; CIBERES, Barcelona, Spain. Electronic address: aagusti@clinic.cat.

Erratum in

Department of Error.
[No authors listed] [No authors listed] Lancet. 2018 Mar 17;391(10125):1022. doi: 10.1016/S0140-6736(18)30318-0. Epub 2018 Feb 14. Lancet. 2018. PMID: 29454593 No abstract available.

No abstract available

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Papi A, et al. Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Lancet. 2018. PMID: 29429593 Clinical Trial.